Cheapest Saxenda vs Mounjaro - UK Price £124.99

Our Pricing

Saxenda vs Mounjaro: Which Weight Loss Injection Is Right for You?

Published on: June 03, 2026

Choosing between saxenda vs mounjaro online prescription uk options requires understanding how each medication works and which suits your weight loss goals. At Cured Pharmacy, our UK-registered clinical team provides free consultations to help you access the right prescription treatment, with transparent pricing and discreet next-day delivery across the UK.

How Saxenda and Mounjaro Work Differently

Saxenda contains liraglutide, a GLP-1 receptor agonist that mimics a natural hormone controlling appetite and blood sugar regulation [1]. Administered as a daily subcutaneous injection, Saxenda has been licensed in the UK since 2015 and demonstrated average weight loss of 8-9% body weight over 56 weeks in the SCALE clinical trials [1].

Mounjaro contains tirzepatide, the UK's first dual GIP/GLP-1 receptor agonist, activating two hormone pathways simultaneously [2]. This dual mechanism produces significantly greater weight reduction than single-pathway treatments. In the SURMOUNT-1 trial, participants achieved average weight loss of up to 22.5% over 72 weeks on the highest dose — substantially higher than liraglutide-based alternatives [2][3].

The key difference lies in dosing frequency and mechanism: Saxenda requires daily injections at a maximum 3mg dose, whilst Mounjaro is administered once weekly with doses escalating up to 15mg. Both medications require prescription approval from a UK-registered prescriber following clinical assessment.

Saxenda vs Mounjaro: Clinical Efficacy Comparison

Head-to-head clinical data shows tirzepatide consistently outperforms liraglutide for weight reduction. In trials comparing GLP-1 receptor agonists, tirzepatide demonstrated 2-3 times greater average weight loss than liraglutide at comparable timeframes [2][3].

Saxenda clinical trials showed that 63% of participants lost at least 5% body weight over 56 weeks, with average reductions of 8-9% when combined with lifestyle modifications [1]. Participants typically reach maximum effect within 6-8 months of daily treatment.

Mounjaro trials revealed more substantial outcomes: in SURMOUNT-1, 89% of participants on the 15mg dose achieved at least 5% weight loss, with 57% losing over 20% of their starting body weight [3]. The dual receptor mechanism appears to produce both greater appetite suppression and improved metabolic regulation compared to single-pathway treatments.

Real-World Weight Loss Expectations

Clinical trial results represent controlled conditions with structured diet and exercise programmes. Real-world outcomes vary based on individual adherence, lifestyle modifications, and metabolic factors. Your UK prescriber will set realistic expectations during your consultation, considering your medical history, current BMI, and weight loss goals. Both medications work best when combined with sustainable dietary changes and regular physical activity.

Side Effects: What to Expect from Each Treatment

Both Saxenda and Mounjaro share common gastrointestinal side effects due to their GLP-1 activity, though severity and duration differ between individuals. The most frequently reported adverse effects include nausea, diarrhoea, constipation, vomiting, and abdominal discomfort [1][2].

Saxenda users typically experience peak side effects during dose escalation in weeks 1-5, with symptoms often diminishing as the body adapts to the 3mg maintenance dose. Approximately 40-50% of participants in SCALE trials reported nausea, though most cases were mild to moderate and resolved within weeks [1].

Mounjaro's once-weekly administration may produce more pronounced but less frequent side effects compared to daily injections. In SURMOUNT trials, gastrointestinal events were most common during dose increases, affecting approximately 60% of participants [3]. The slower dose escalation schedule (increasing every 4 weeks) helps minimise adverse effects whilst maintaining efficacy.

Rare but serious risks include pancreatitis, gallbladder disease, and thyroid tumours (observed in animal studies). Both medications carry warnings about medullary thyroid carcinoma and are contraindicated in patients with personal or family history of this condition [1][2]. Your UK prescriber will assess your complete medical history before determining suitability for either treatment.

Managing Side Effects Effectively

Starting with lower doses and escalating gradually significantly reduces gastrointestinal symptoms. Eating smaller, more frequent meals and avoiding high-fat foods can minimise nausea. If side effects persist beyond the initial weeks or become severe, contact your prescriber immediately — dose adjustment or alternative treatments may be more appropriate for your circumstances.

Dosing Schedules and Administration

Saxenda requires daily subcutaneous injections, starting at 0.6mg and increasing weekly by 0.6mg increments until reaching the 3mg maintenance dose at week 5. Injections are self-administered into the abdomen, thigh, or upper arm at any time of day, though consistency helps maintain stable blood levels [1].

Mounjaro follows a once-weekly injection schedule, beginning at 2.5mg and increasing every 4 weeks based on tolerability and clinical response. Doses escalate through 5mg, 7.5mg, 10mg, 12.5mg, and maximum 15mg strengths. The KwikPen device delivers pre-measured doses, reducing administration errors [2].

Both treatments come in pre-filled, single-use pens requiring refrigeration before first use. Saxenda pens contain multiple doses and last approximately 6 days at the 3mg maintenance dose, whilst each Mounjaro pen delivers one weekly injection. Proper injection technique and site rotation prevent lipodystrophy and ensure consistent absorption.

Cost Comparison and UK Pricing

At Cured Pharmacy, Mounjaro starts from £124.99 per pen with transparent upfront pricing before your consultation. Saxenda is available from £135.00 offering a more accessible entry point for patients beginning weight loss treatment. Final costs depend on your prescribed dose and treatment duration, determined by your UK prescriber during clinical assessment.

Monthly treatment costs vary based on dosing: Saxenda requires approximately 5 pens monthly at maintenance dose, whilst Mounjaro typically needs 4 pens per month for once-weekly dosing. When comparing overall treatment expense, consider both per-pen pricing and the frequency of administration required to maintain therapeutic levels.

Cured Pharmacy guarantees the lowest prices in the UK for genuine, MHRA-licensed medications. Unlike some providers, we display all costs before you begin your consultation — no hidden fees, no surprise charges at checkout. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets UK regulatory standards whilst maintaining competitive pricing.

Is Weight Loss Treatment Cost-Effective?

Clinical studies demonstrate that prescription weight loss medications may reduce long-term healthcare costs by preventing obesity-related conditions including type 2 diabetes, cardiovascular disease, and joint problems [4]. When combined with sustained lifestyle changes, the initial investment in treatment can produce lasting health improvements that extend well beyond the prescription period. Your UK prescriber will discuss realistic treatment timelines and expected outcomes during your consultation.

Getting Your Saxenda vs Mounjaro Online Prescription UK

Accessing prescription weight loss treatment through Cured Pharmacy takes under 3 minutes. Complete our free online consultation answering questions about your medical history, current medications, weight loss goals, and any contraindications. Our UK-registered prescribers review every submission individually — this isn't an automated process.

Eligible patients receive same-day prescription approval, with medications dispensed from our GPhC-registered pharmacy (registration 9012511) and dispatched via discreet next-day delivery. All packaging is plain and unmarked, protecting your privacy throughout the process.

Your prescriber will determine which treatment suits your individual circumstances based on BMI, medical history, previous weight loss attempts, and tolerance for injection frequency. Some patients prefer Saxenda's daily routine and lower starting cost, whilst others prioritise Mounjaro's once-weekly convenience and superior clinical outcomes. Both options require ongoing monitoring and follow-up consultations to ensure safe, effective treatment.

If you're currently taking other medications, have existing health conditions, or have previously used weight loss treatments, disclose this information during your consultation. Certain conditions including medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease may contraindicate GLP-1 treatments. Your UK prescriber will recommend the safest, most effective option for your specific situation.

Scientific References

1. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11-22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613-626. https://doi.org/10.1016/S0140-6736(23)01200-X [accessed 13 August 2026]
4. Keating, C., Neovius, M., Sjöholm, K., et al. (2015). Health-care costs over 15 years after bariatric surgery for patients with different baseline glucose status: results from the Swedish Obese Subjects study. The Lancet Diabetes & Endocrinology, 3(11), 855-865. https://doi.org/10.1016/S2213-8587(15)00290-9 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, lifestyle modifications, and individual metabolic factors.